Johnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in China

The three strategic collaborations are focused on leveraging advances in science and technology to address areas of high unmet medical need …
Johnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in ChinaJohnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in China
Front row (left to right): Jian Chen, Vice President, Xian Janssen Pharmaceuticals; Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific; Sharona Tao, Leader, Communications & Public Affairs, Johnson & Johnson China; Jennifer Yang, Head, Lung Cancer Initiative China, Johnson & Johnson Back row (left to right): Alex Zhavoronkov, Founder & CEO, Insilico Medicine; Li Peng, Assistant General Manager, Taikang Online Insurance; Gary Ge, Founder, Diannei

What You Should Know:

– Johnson & Johnson Innovation announces three strategiccollaborations with a focus on advancing healthcare solutions in China.

– The three strategic collaborations are focused on leveraging advances in science and technology to address areas of high unmet medical need across several areas, including discovery science, lung cancer, and medical devices


Johnson & Johnson Innovation, a division of Johnson & Johnson (China) Investment Limited, today announced three new collaborations with strategic partners in China. These latest collaborations, facilitated by the Johnson & Johnson Asia Pacific Innovation Center, showcase its broad innovation efforts and focus on leveraging advances in science and technology to address areas of high unmet medical need across several areas, including discovery science, lung cancer, and medical devices.

The collaborations are as follows:

1. Leveraging AI in drug discoveryJanssen Pharmaceutica NV, one of theJanssen Pharmaceutical Companies of Johnson & Johnson, has established amulti-target drug discovery collaboration with Insilico Medicine Hong KongLtd., a Johnson & Johnson Innovation – JLABS @ Shanghai residentcompany specializing in AI-based drugdiscovery.

The agreement will leverage Insilico Medicine’s AI-based platform to design small-molecule hits with the defined properties for several targets nominated by Janssen. The collaboration aims to generate novel and fully patentable chemical scaffolds for difficult targets using AI-based drug designing, potentially leading to significant reductions in time and cost in identifying biologically active hits against selected targets.

2. Developing AI solutions for lung cancer detection– The Lung Cancer Initiative at Johnson & Johnson in China,through its affiliate Johnson & Johnson (China) Investment Limited, has enteredinto a research collaboration with Diannei (Shanghai) Biotechnology Co. Ltd., aChinese company specializing in AI solutions for lung cancer management. Theagreement will see both parties work together to develop computer vision AI forlung cancer diagnosis. Diannei’s expertise is in developing AI solutions withdeep learning for medical image analysis.

3. Innovative healthcare solutions for sports injury– Johnson & Johnson Medical (Shanghai) Limited (JJMS) announced anagreement with Taikang Online Insurance Co. Ltd. (Tk.cn), a Chinese onlinehealthcare insurance company, to develop an innovative sports injury-relatedinsurance package. JJMS will support Tk.cn by offering its industrial insights,while Tk.cn designs reimbursement coverage to sports enthusiasts which aim toenable timely diagnosis and appropriate surgical treatment for patients.

Why It Matters

“Johnson & Johnson has deep roots in China for the past 35 years to address the growing needs of patients and consumers. We are delighted to mark the third annual CIIE, a significant platform that supports the expansion, innovation and internationalization of the Chinese business environment, by announcing these new collaboration agreements,” said Will Song, Global Senior Vice President, China Chairman, Johnson & Johnson*. “These agreements span a diverse range of focus areas and represent a valuable opportunity to advance human health for the country by connecting global and local innovators with the expertise of the Johnson & Johnson Family of Companies to help transform great ideas into breakthrough solutions.”